Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615616 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 24 Pages |
Abstract
Most patients with acute myeloid leukemia with intermediate-risk cytogenetics received allogeneic HCT, which decreased the risk of relapse but increased NRM, leading to a similar overall survival for patients who received HCT and HIDAC. Our data support the use of allogeneic transplantation for patients in CR1 from a human leukocyte antigen-matched related or unrelated donor after a busulfan-based myeloablative conditioning regimen as a primary strategy of postremission therapy for eligible younger patients.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jan Vydra, Cyril Å álek, JiÅà Schwarz, Pavel Žák, Jan Novák, Veronika PeteÄuková, Pavla Pecherková, JiÅà Mayer, Petr Cetkovský, ZdenÄk RáÄil,